Drug Trial Radar · NCT01177098
Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: Mar 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
561
Actual
Start
Oct 2010
Primary completion
Feb 2012
Study completion Feb 2012
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 6, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A ophthalmic solution with Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once daily for 12 weeks in patients with glaucoma or ocular hypertension.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
bimatoprost /timolol formulation A fixed combination ophthalmic solutionDrug
One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
bimatoprost/timolol fixed combination ophthalmic solutionDrug
One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12Time frame: Baseline, Week 12
- Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2Time frame: Week 2
- Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6Time frame: Week 6
- Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12Time frame: Week 12
Locations
9 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Artesia, California
Site not named
Sydney, New South Wales, Australia
Site not named
Brno, Czechia
Site not named
Leipzig, Germany
Site not named
Budapest, Hungary
Site not named
Tel Aviv, Israel
Site not named
Saint Petersburg, Russia
Site not named
Valencia, Spain
Site not named
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.